Specifically, CAR-T cell therapy targeting CD19 has demonstrated favorable efficacy in both relapsed or refractory PCNSL and secondary central nervous system lymphoma (SCNSL) (7–9). Here, CD19 is linked to primary central nervous system lymphoma.